Pfizer advances tilrekimig after positive mid-stage eczema trial

Why it matters

The result moves a Pfizer inflammation candidate toward later-stage testing across several indications. The company’s planned development program makes subsequent trial execution and safety results the next key milestones for the asset.

Key facts

• 1Pfizer said tilrekimig produced a statistically significant improvement in EASI-75 at Week 16 versus placebo at every evaluated dose. benzinga.com
• 2In the first trial stage, 62.5% of patients receiving 450 mg of tilrekimig every two weeks achieved EASI-75, compared with 19.9% on placebo. benzinga.com
• 3In the monthly-dose stage, EASI-75 rates were 58.5%, 61.0%, and 47.8% for the 400 mg, 200 mg, and 50 mg cohorts, respectively, versus 9.1% for placebo. benzinga.com
• 4Pfizer is moving tilrekimig into Phase 3 studies for atopic dermatitis and asthma and has a Phase 2b/3 COPD study under way. financial-news.co.uk
• 5Pfizer described tilrekimig as generally well tolerated and reported no dose-related safety pattern. gurufocus.com

Open questions

• Reports differ on the timing and status of the planned Phase 3 program, with one describing studies as already running while another says the asthma study is not yet recruiting.
• Safety descriptions are not fully aligned, as one report highlights higher adverse-event reporting in an earlier stage while another characterizes rates as comparable with placebo.】【：】【“】【],
• importance":7,
• category":"technology","numbers_verified_from_materials":true} 天天中彩票不能买ലയാളassistant to=analysis code񎙇់ 天天中彩票中大奖? Nope malformed draft! Need correct JSON. Also accidental. Need final. Ensure exact syntactic. Need no index in uncertainty. Fine. Category other maybe technology. Return. +#+#+#+#+#+assistant final 天天中彩票足彩{Jsii{